Twist Bioscience Reports 22% Fiscal 2026 Revenue Growth to $459.4 Million

What happened

Twist Bioscience reported fiscal 2026 revenue of $459.4 million, up 22% from the prior year. Full-year gross margin, the share of revenue remaining after direct costs, rose to 52.4%; fourth-quarter adjusted EBITDA, an earnings measure excluding certain costs, was positive $2.2 million. The company forecast fiscal 2027 revenue of $550 million to $560 million and positive adjusted EBITDA.

Confirmed

Global impact / market context

The revenue forecast points to continued sales growth, while expected positive adjusted EBITDA would mark progress toward covering operating costs with the business’s earnings before certain expenses. However, the reported fiscal 2026 net loss widened, so investors may weigh growth and improving gross margin against the continuing overall loss.

Analyst inference

Twist’s reported revenue grew 22%, and its gross margin improved, but fiscal 2026 net loss increased to $130.2 million from $77.7 million. That combination leaves the investment case dependent not just on sales growth, but on whether growth translates into better overall financial results.

Analyst inference

What to watch

1. Compare reported fiscal 2027 revenue with the $550 million to $560 million forecast; results below that range could weaken the outlook for sales growth. Analyst inference
2. Check whether adjusted EBITDA turns positive for fiscal 2027 as forecast, and whether any improvement accompanies reduced operating and net losses. Analyst inference
3. Track gross margin against fiscal 2026’s 52.4%; a decline could mean direct costs are consuming more of each revenue dollar. Analyst inference

Evidence

• Original source link unavailable